Irritable Bowel Syndrome

IBS is considered 1 of the most expensive conditions in gastroenterology.

Data show patients with chronic IBS had six times the odds of developing glaucoma (OR 6.58; 95% CI, 2.00 - 16.89), in comparison to those without chronic IBS.

Advice for community physicians and gastroenterologists to help manage patients with ulcerative colitis.

The significance of conducting future head-to-head trials of therapies used to treat inflammatory bowel disease and implications for treating ulcerative colitis (UC) with vedolizumab based on recent data demonstrated when the drug was tested in a first-ever head-to-head biologic clinical study in UC.

The rationale for treating inflammatory bowel disease with ustekimumab based on more recent safety and efficacy data demonstrated by a trial that followed patients for up to 5 years.

Sucrase isomaltase deficiency is often overlooked symptom in adult patients with IBS-D.

Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.

Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.

Data show a 23.5% increase in influenza vaccination rates.

Data show biologic therapy was not associated with ICU admission or death due to infection.

Linaclotide has been marketed as LINZESS to treat irritable bowel syndrome with constipation.

In data presented at ACG, investigators found a link between sex, lower BMI, and the development of irritable bowel syndrome in patients following a c. diff infection.